| An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) |
Rejected |
Mirabegron |
3 |
178-CL-206A |
N\A |
| "randomised, multicentre, double-blind, placebo-controlledstudy of ambrisentan in subjects with inoperable chronicthromboembolic pulmonary hypertension (CTEPH)" |
Terminated |
Ambrisentan 5 mg |
3 |
AMB115811 |
N\A |
| Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE) |
Rejected |
Dexmedetomidine |
3 |
RC11/084 |
N\A |
| A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes. |
Rejected |
Cannabidiol & Tetrahydrocannabivarin |
2a |
GWZMD1190 |
N\A |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome |
Rejected |
Alogliptin |
3 |
SYR-322_402 |
N\A |
| "A RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED, PILOT, DOSE-RANGING STUDY TO ASSESS THE EFFECT OF GWP42003 ON LIVER FAT LEVELS IN SUBJECT WITH FATTY LIVER DISEASE" |
Rejected |
Cannabidiol |
2a |
GWZMD1188 |
N/A |
| A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. |
Rejected |
Everolimus + Exemestane\Everolimus\Capecitabine |
2 |
CRAD001Y2201 |
N\A |
| A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age |
Rejected |
Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612 |
3b |
114858 |
N\A |
| "Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial" |
Ongoing |
(Cyklokapron) Tranexamic Acid |
3 |
ISRCTN15088122 |
King Saud Medical City (Riyadh) |
| "“MERS-CoV Infection Treated with a Combination ofLopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-BlindRandomized Trial (MIRACLE Trial)”" |
Ongoing |
Kaletra |
3 |
RC15/142/R |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital NG (Al Ahsa), Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Genaral Hospital, Medina, prince mohammad bin abdulaziz hospital (Riyadh), ohud hospital (Medina), Buraidah Central Hospital HOME - Buraydah, Aseer Central Hospital |
